Discussion on PharmEasy Unlisted Shares:

Apollo Hospitals Enterprise which runs a competitor platform called Apollo 247, along with the biggest hospital chain, biggest pharmacy chain, diagnostic services, specialty clinics, telehealth, R&D centres - everything built in-house and profitable - is currently valued around $7 billion. Why should I buy a cash burning medicine delivery company at $5.6 billion valuation?

What is the fate of this company now? Can it survive Reliance (since Netmeds is owned by reliance)?

What is the p/s ratio of pharmeasy ?

Summary of objections faced by PharmEasy to date September 2020: PharmEasy’s merger with MedLife merger was approved despite opposition from the SCDA which had argued that online pharmacies were not allowed under the law, and hence the CCI cannot permit “combination for an illegal purpose”. In a representation to the CCI, the association had said that the proposed merger is essentially “that of two e-pharmacies as well as companies involved in the distribution chain”. It also said that the deep discounting by e-pharmacies can harm competition, given that these “are not based on any efficient business model but solely due to cash burn thanks to investment from foreign-based entities”. July 2021: PharmEasy’s acquisition of Thyrocare was opposed by SCDA in a letter sent to CCI asking the regulatory body to reject the acquisition because e-pharmacies are not legal under Indian law and therefore the proposed acquisition needs to be rejected. It also claimed that allowing PharmEasy to acquire Thyrocare would result in dominance in the market by API Holdings. November 2021: SCDA again asked SEBI to reject the initial public offering (IPO) of PharmEasy on the grounds that online pharmacies are not legal under Indian law as per a letter sent by the association. The association lists the same reasons as it does in the petition in pleading its case. December 2021: The Confederation of All India Traders (CAIT) wrote to SEBI a few weeks ago asking the regulator to reject the initial public offering (IPO) of API Holdings, owner of PharmEasy, arguing that the online pharmacy’s business model is “entirely based on gross illegality.”

Medplus Health being Second Largest pharmacy retailer .... valued at around $1.2-1.3B can we compare this with Pharmeasy from unlisted stock (at 110-120/- per share) is valued at $9-10B ? I have heard good review about Medplus compared to other options... Pharmeasy Total Revenue for March 2021 = 2360cr Net Profit = -641cr (loss) As mentioned in Medplus IPO Total Revenue Rs. 3090.81 cr. / Rs. 63.11 cr. for March 2021

Around One month back Pharmeasy raised fund at $5.6B and today @130/- it is almost approx valued at $10.6B Pharmeasy has already filed for IPO... so i just hope it doesnt happen like Policy Bazar and Paytm. Just before IPO all such startups has given negative returns... even Finopay.. So always better to enter much before IPO... atleast minimum a year

Hi, I am interested to buy. could you please share the price ?

What is the price ?

Hello Do u have the lastest Shareholding Pattern and Balance Sheet?

PharmEasy, India’s largest online pharmacy, has nearly doubled its revenue in FY20 to Rs 637 crore although its losses also increased during the same period, according to documents viewed by Moneycontrol. PharmEasy’s trading entity, run by Thea Technologies Pvt. Ltd, earned Rs 637 crore in FY20 - compared to Rs 340 crore in FY19, according to its unaudited financial statements. Its losses before tax for the period also doubled to Rs 100.7 crore from Rs 50 crore a year earlier. The FY20 numbers, ending March 31, only factor in a small portion of the coronavirus lockdown while the last six months have been a busy time for the industry amid fundraises, acquisitions and orders going through the roof. Compared to other online pharmacies, at least on paper, PharmEasy has been able to keep its cash burn and losses in check. A loss of Rs 100 crore on revenue of Rs 640 crore of revenue is better compared to rivals Medlife (which PharmEasy is acquiring) and Sequoia Capital-backed 1mg. For FY19. Medlife’s revenue grew 165% to Rs 363 crore, on a loss of Rs 404 crore, while 1mg more than doubled to Rs 240 crore in FY19, while losses also almost doubled to Rs 170 crore.

Online pharmacy PharmEasy’s parent will buy a 66.1% stake in diagnostic chain Thyrocare Technologies for ₹4,546 crore, in a sign that Indians are increasingly using mobile apps for their healthcare needs.

In 2019, to give competition to Reliance Retail acquired Net-Meds, Amazon, Flipkart etc. 5 companies decided to merge and formed an alliance called API Holdings and PharmEasy was one of them.